Literature DB >> 1314492

Activation of multiple mechanisms including phospholipase D by endothelin-1 in rat aorta.

Y Liu1, B Geisbuhler, A W Jones.   

Abstract

This study investigated the cellular mechanisms underlying the endothelin-1 (ET-1)-induced contraction of rat aorta with focus on the involvement of phospholipase D (PLD). Preincubating rat aorta in Ca(2+)-free solution reduced the contraction by 80%, whereas diltiazem (10 microM), a voltage-operated Ca2+ channel blocker, caused only a small reduction (27%, P less than 0.05) of the contraction. In myo-[3H]inositol-labeled aorta, ET-1 stimulated the formation of [3H]inositol bisphosphate and [3H]inositol trisphosphate, indicating the activation of phospholipase C (PLC). In aorta labeled with 32PO4, [3H] myristic acid or [32P]lyso-platelet-activating factor followed by exposure to ethanol (0.5%), ET-1 stimulated phosphatidylethanol (PEt) production, suggesting that ET-1 activates PLD. The PEt response was not attenuated by staurosporine (ST, 0.1 microM), an inhibitor of protein kinase C (PKC) but was inhibited by removal of Ca2+. The ET-1-induced PEt response was at least additive to that induced by phorbol 12-myristate 13-acetate (1 microM). ET-1 also stimulated the release of 6-ketoprostaglandin F1 alpha (6-keto-PGF1 alpha) into the tissue medium. Unlike the PEt responses, the 6-keto-PGF1 alpha response could be inhibited by ST. Removal of Ca2+ abolished the response. These results suggest that 1) ET-1 activates multiple cellular mechanisms including PLC, PLD, and the arachidonate cascade; 2) PKC activation may not be essential for the ET-1 activation of PLD but may play an important role in the ET-1 stimulation of 6-keto-PGF1 alpha release; and 3) Ca2+ is an important factor in the ET-1-induced PLD activity and 6-keto-PGF1 alpha release.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314492     DOI: 10.1152/ajpcell.1992.262.4.C941

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Regulation and functional significance of phospholipase D in myocardium.

Authors:  Y E Eskildsen-Helmond; H A Van Heugten; J M Lamers
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

2.  Inhibition of endothelin- and phorbol ester-stimulated tyrosine kinase activity by corticotrophin in the rat adrenal zona glomerulosa.

Authors:  S Kapas; J P Hinson
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

Review 3.  Endothelin and heart failure.

Authors:  P Nambi; M Clozel; G Feuerstein
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

4.  Endothelin-1 induces tyrosine phosphorylation in human blood monocytes.

Authors:  L J Chisholm; D K Agrawal; T J Pearson; J D Edwards
Journal:  Mol Cell Biochem       Date:  1996-06-07       Impact factor: 3.396

Review 5.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

6.  Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade.

Authors:  N H Garcia; J L Garvin
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Wounding sheets of epithelial cells activates the epidermal growth factor receptor through distinct short- and long-range mechanisms.

Authors:  Ethan R Block; Jes K Klarlund
Journal:  Mol Biol Cell       Date:  2008-09-17       Impact factor: 4.138

8.  Bradykinin stimulates phospholipase D in PC12 cells by a mechanism which is independent of increases in intracellular Ca2+.

Authors:  J Horwitz; B Passarello; M Corso
Journal:  Neurochem Res       Date:  1995-09       Impact factor: 3.996

9.  Prostaglandin F2 alpha-stimulated phospholipase D activation in osteoblast-like MC3T3-E1 cells: involvement in sustained 1,2-diacylglycerol production.

Authors:  T Sugiyama; T Sakai; Y Nozawa; N Oka
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.